PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Disorders of Excessive Somnolence

Drugs in development · updated 30 October 2026

Disorders of Excessive Somnolence: drugs in development

As of 30 October 2026 there are 15 active clinical trials (recruiting or ongoing, phases I–III) on 10 drugs for disorders of Excessive Somnolence. 8 are experimental, that is not yet approved in the United States.

15Active trials
8Experimental drugs
5Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
ALKS 2680II–III5NCT06767683
BerobenatideIII1NCT07881757
CleminorextonII–III1NCT07598708
HBS-301III1NCT07500090
SamelisantIII1NCT07540364
ALKS 7290II1NCT07901179
ORX750II1NCT07096674
ORX142I1NCT07082829

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
SolriamfetolSunosi®III2NCT07484217
PitolisantWakix®, Ozawade®III1NCT06366464

Sorted by most advanced phase and number of active trials.

All 10 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Specific forms

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D006970 “Disorders of Excessive Somnolence”.

ItalianoFrançaisDeutsch